Glimzab MV 1mg/500mg/0.3mg Tablet ER
Marketer
Neucure Lifesciences Private Limited
Salt Composition
Glimepiride (1mg) + Metformin (500mg) + Voglibose (0.3mg)
Overview Glimzab MV 1mg/500mg/0.3mg Tablet ER
Glimzab MV 1mg/500mg/0.3mg Extended-Release Tablets are classified as antidiabetic medications. This combination therapy treats type 2 diabetes in adults by regulating blood glucose. Administer this medication with food, consistently at the same time daily for optimal effectiveness. Dosage is determined by your physician and may be adjusted based on blood sugar monitoring. Continue taking this medication as prescribed, even if feeling well or experiencing controlled blood sugar, as abrupt cessation can elevate blood glucose, potentially leading to kidney complications, vision impairment, neuropathy, and limb loss. This medicine is one component of a comprehensive diabetes management plan, which includes a balanced diet, regular physical activity, and weight management as recommended by your doctor. Lifestyle significantly influences diabetes control. Hypoglycemia (low blood sugar) is the most common adverse effect. Learn to recognize symptoms such as sweating, dizziness, headache, and tremors, and know how to manage them. Regular meals and readily available fast-acting glucose sources (sugary foods or juice) are crucial. Alcohol consumption increases hypoglycemia risk and should be limited. Other potential side effects include altered taste, nausea, diarrhea, abdominal discomfort, headache, edema, blurred vision, fractures, and upper respiratory infections. Weight gain may occur. This medication is contraindicated in type 1 diabetes, diabetic ketoacidosis, and severe renal or hepatic impairment. Disclose any history of heart disease to your physician before initiating treatment. Pregnant or lactating individuals should consult their doctor. Regular blood glucose monitoring is essential, along with potential blood tests to assess blood cell counts and liver function.
Primary Ingredients of Glimzab MV 1mg/500mg/0.3mg Tablet ER
No text provided. Please provide the text you wish me to rephrase.
Uses of Glimzab MV 1mg/500mg/0.3mg Tablet ER
Managing type 2 diabetes
Major Benefits of Glimzab MV 1mg/500mg/0.3mg Tablet ER:
Administer this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment duration. Ingest the entire tablet without chewing, crushing, or fracturing it. Consume the Glimzab MV 1mg/500mg/0.3mg Extended-Release tablet on an empty stomach.
Common Side effects of Glimzab MV 1mg/500mg/0.3mg Tablet ER:
- Nausea
- Diarrhea
- Abdominal pain
- Hypoglycemia (low blood glucose level)
- Loss of appetite
How to use Glimzab MV 1mg/500mg/0.3mg Tablet ER:
Administer this medication precisely as prescribed by your physician, adhering to both dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing. Consume Glimzab MV 1mg/500mg/0.3mg Extended-Release Tablets on an empty stomach.
How Glimzab MV 1mg/500mg/0.3mg Tablet ER works:
Extended-release Glimzab MV tablets (1mg/500mg/0.3mg) contain a triple-action formulation for diabetes management.
SAFETY ADVICE
AlcoholUNSAFE
Combining Glimzab MV 1mg/500mg/0.3mg Tablet ER with alcohol is not advisable due to safety concerns.
PregnancyCONSULT YOUR DOCTOR
Extended-release Glimzab MV tablets (1mg/500mg/0.3mg) may pose pregnancy risks. While human data is scarce, animal research indicates potential harm to a fetus. Prescribing will involve a physician's assessment of benefits against potential hazards. Seek medical advice before taking this medication.
Breast feedingCONSULT YOUR DOCTOR
Extended-release Glimzab MV tablets (1mg/500mg/0.3mg) are likely unsafe for breastfeeding mothers. Available evidence from humans indicates potential transfer to breast milk, posing a risk to the infant.
DrivingCAUTION
Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these blood sugar imbalances.
KidneyUNSAFE
Extended-release Glimzab MV 1mg/500mg/0.3mg tablets are likely unsafe for individuals with kidney impairment and should be omitted. Medical advice is necessary. Furthermore, this medication is unsuitable for those with severe kidney disease.
LiverCAUTION
Patients with liver impairment should use Glimzab MV 1mg/500mg/0.3mg Tablet ER cautiously, potentially requiring dosage modification. A physician's consultation is advised. For those with mild to moderate hepatic dysfunction, initiation should be at a reduced dosage; it's contraindicated in patients with severe liver disease.
What if you forget to take Glimzab MV 1mg/500mg/0.3mg Tablet ER :
Should you forget a Glimzab MV 1mg/500mg/0.3mg Extended-Release Tablet, administer it immediately upon remembrance. Nevertheless, if your next scheduled dose is imminent, omit the missed tablet and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Glimzab MV 1mg/500mg/0.3mg Tablet ER
| Label | Value |
|---|---|
| Developing Habits | No. |
| Type of Therapy | Diabetes Management |
3,018 People bought this recently